the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)

Pre-clinicalRecruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia

Trial Timeline

Dec 21, 2023 → Dec 31, 2025

NCT ID

NCT06206135

About the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)

the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) is a pre-clinical stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06206135. Target conditions include Hyperphosphatemia.

What happened to similar drugs?

2 of 15 similar drugs in Hyperphosphatemia were approved

Approved (2) Terminated (0) Active (13)

✅Tenapanor + Sevelamer CarbonateArdelyxApproved

✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved

🔄KHK7791 + PlaceboKyowa KirinPhase 3

🔄KHK7791Kyowa KirinPhase 3

🔄SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06206135	Pre-clinical	Recruiting	Dec 21, 2023	Dec 31, 2025	Hyperphosphatemia

Competing Products

20 competing products in Hyperphosphatemia

See all competitors

Product	Company	Stage	Hype Score
EOS789 + Placebo + Renvela	Chugai Pharmaceutical	Phase 1	29
DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet	Daiichi Sankyo	Phase 1	29
ASP1585 + Placebo + Sevelamer hydrochloride	Astellas Pharma	Phase 2	35
ASP1585	Astellas Pharma	Phase 2	35
the standard-dose group (4 g/day)	Kyowa Kirin	Pre-clinical	33
KHK7791 + Placebp	Kyowa Kirin	Phase 2	35
KHK7791	Kyowa Kirin	Phase 2	35
KHK7791 + Placebo	Kyowa Kirin	Phase 3	40
KHK7791 + Placebo	Kyowa Kirin	Phase 3	40
KHK7791	Kyowa Kirin	Phase 3	40
KHK7791 + Placebo	Kyowa Kirin	Phase 2	35
KHK7791	Kyowa Kirin	Phase 3	40
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl	Novartis	Phase 2	35
SBR759A + SBR759A + SBR759A + SBR759A + SBR759A	Novartis	Phase 3	40
PA21	Kissei Pharmaceutical	Phase 3	40
Placebo + Sevelamer Carbonate (GZ419831)	Sanofi	Phase 3	40
Placebo + Sevelamer carbonate	Sanofi	Phase 2	35
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet	Bayer	Pre-clinical	23
Lanthanum Carbonate (Fosrenol, BAY77-1931)	Bayer	Pre-clinical	23
Lanthanum Carbonate (BAY77-1931)	Bayer	Phase 2	32